Evidence map›Paper›PMID 33330063›Full record

ArticleFrontiers in oncology2020

BaBao Dan Suppresses Tumor Growth of Pancreatic Cancer Through Modulating Transcriptional Reprogramming of Cancer-Related Genes.

Libin Song, Zhixiao Fang, Chuanfang Pan, Xiangyuan Chen, Xiang Qian, Yunyun Cai, Xiumei Zhang, Luming Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Libin SongDepartment of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Zhixiao FangInstitute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chuanfang PanDepartment of Oncology, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiangyuan ChenDepartment of Geriatrics, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Xiang QianInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Zheijang, China.
Yunyun CaiDepartment of Integrated Traditional Western Medicine, Minhang Branch of Fudan University of Shanghai Cancer Center, Shanghai, China.
Xiumei ZhangDepartment of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Luming LiuDepartment of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Fudan University Shanghai Cancer Center · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFudan University · CNLonghua Hospital Shanghai University of Traditional Chinese Medicine · CNShanghai Jiao Tong University · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsPancreatic ductal adenocarcinoma (PDAC) is one of refractory malignancies without efficient therapeutics. Babao Dan (BBD) was partially effective to suppress tumor growth of PDAC in clinical practice. However, the molecular mechanisms were unclear.

methodsWe established PDAC mice models and treated them with BBD through intragastric administration. Treatment and control groups were then subjected to high-throughput RNA sequencing. We presented the transcriptional changes upon BBD treatment by using computational analysis comparing BBD treatment and control groups. Functional enrichment analysis was employed to investigate the biological processes or pathways that BBD modulates.

resultsBBD treatment showed strong suppression on tumor growth of PDAC, even stronger than Gemcitabine. Through differential analysis comparing BBD treatment and control groups, we identified 638 up-regulated and 259 down-regulated genes in the BBD treatment group. BBD was found to activate tumor suppressor genes, such as MTUS1, PDGFB, SOD3, and UCHL1. Furthermore, we revealed that BBD treatment inhibited cancer-related pathways and elevated activities of metabolism-related processes. The BBD-modulated metabolic genes were further showed to be associated with patient survival in an independent cohort with pancreatic cancer.

conclusionBBD repressed the tumor growth of PDAC. BBD treatment modulated expression of cancer-related genes in PDAC. BBD suppressed cancer-related pathways and activated metabolic processes in PDAC. Our study suggests BBD treatment as potential effective therapeutics for patients with pancreatic cancer.

Indexed as

Babao Danenrichment analysismetabolismpancreatic cancertranscriptome

Identifiers

PMID33330063
PMCPMC7710661
OpenAlexW3105477388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.